Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance

Eijiro Yamada, Ting Wen A Lee, Jeffrey E. Pessin, Claire C. Bastie

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.

Original languageEnglish (US)
Pages (from-to)1785-1796
Number of pages12
JournalFuture Medicinal Chemistry
Volume2
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

AMP-Activated Protein Kinases
Type 2 Diabetes Mellitus
Insulin Resistance
Phosphotransferases
Obesity
Sedentary Lifestyle
Protein-Serine-Threonine Kinases
Liver
Metabolic Diseases
Lipid Metabolism
Vascular Resistance
Therapeutics
Insulin
Glucose
Incidence
Serum

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance. / Yamada, Eijiro; Lee, Ting Wen A; Pessin, Jeffrey E.; Bastie, Claire C.

In: Future Medicinal Chemistry, Vol. 2, No. 12, 12.2010, p. 1785-1796.

Research output: Contribution to journalArticle

Yamada, Eijiro ; Lee, Ting Wen A ; Pessin, Jeffrey E. ; Bastie, Claire C. / Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance. In: Future Medicinal Chemistry. 2010 ; Vol. 2, No. 12. pp. 1785-1796.
@article{a0a2a4ad61ff4e0ebd3f48b5eb75dce5,
title = "Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance",
abstract = "Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.",
author = "Eijiro Yamada and Lee, {Ting Wen A} and Pessin, {Jeffrey E.} and Bastie, {Claire C.}",
year = "2010",
month = "12",
doi = "10.4155/fmc.10.264",
language = "English (US)",
volume = "2",
pages = "1785--1796",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "12",

}

TY - JOUR

T1 - Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance

AU - Yamada, Eijiro

AU - Lee, Ting Wen A

AU - Pessin, Jeffrey E.

AU - Bastie, Claire C.

PY - 2010/12

Y1 - 2010/12

N2 - Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.

AB - Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.

UR - http://www.scopus.com/inward/record.url?scp=78650217374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650217374&partnerID=8YFLogxK

U2 - 10.4155/fmc.10.264

DO - 10.4155/fmc.10.264

M3 - Article

VL - 2

SP - 1785

EP - 1796

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 12

ER -